Amicus Therapeutics’ (FOLD) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report released on Monday morning,Benzinga reports.

A number of other research firms also recently issued reports on FOLD. Bank of America boosted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald increased their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.27 on Monday. The business’s 50-day moving average price is $9.81 and its 200 day moving average price is $10.54. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.03. The company has a market capitalization of $2.77 billion, a PE ratio of -27.26 and a beta of 0.62.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,161,054.84. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in Amicus Therapeutics by 4.7% in the second quarter. Rhumbline Advisers now owns 434,612 shares of the biopharmaceutical company’s stock valued at $4,311,000 after acquiring an additional 19,491 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Amicus Therapeutics by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Amicus Therapeutics during the second quarter worth about $89,000. Envestnet Asset Management Inc. grew its stake in Amicus Therapeutics by 3.7% in the second quarter. Envestnet Asset Management Inc. now owns 450,823 shares of the biopharmaceutical company’s stock worth $4,472,000 after purchasing an additional 16,263 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Amicus Therapeutics by 14.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock valued at $29,964,000 after buying an additional 378,999 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.